ArticleFrontiers in neurology
Silent refractoriness in epilepsy care: cross-sectoral analysis of prescribing patterns, referrals and workforce capacity in Saxony.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epilepsy care in Germany is structured through a delegated outpatient model in which long-term management is primarily delivered by office-based neurologists and general practitioners, while specialized epilepsy centers provide escalation for complex cases. Whether this structure enables timely access to advanced therapies in high-burden regions remains unclear. Objective: To evaluate structural disparities in prescribing patterns, referral behavior, and workforce distribution in Saxony, a federal state with above-average epilepsy prevalence and treatment intensity. Methods: We conducted a cross-sectoral analysis integrating IQVIA LRx® prescription data (2024), Disease Analyzer prevalence estimates, and anonymized outpatient referral data from the state's only DGfE-certified epilepsy center (Kleinwachau). Utilization was assessed using Days of Therapy (DOT), with a focus on levetiracetam (LEV) as a proxy for focal epilepsy care. Workforce distribution was estimated using Bundesärztekammer data. Findings were contextualized through a multidisciplinary expert panel. Results: Despite high treatment intensity, substantial gaps in escalation were observed. While approximately 36% of patients met a pharmacological proxy for drug resistance, only a minority accessed specialized center care. Prescribing patterns showed a persistent preference for LEV across all sectors, with marked regional variation in LEV: lamotrigine ratios that aligned with levels of specialization and proximity to the epilepsy center. Adoption of newer antiseizure medications was concentrated in specialized hubs. Referral activity remained uneven, with several regions demonstrating minimal connectivity to formal escalation pathways. Conclusion: Epilepsy care in Saxony is characterized by "silent refractoriness," in which therapy-resistant patients remain in decentralized care without systematic progression to specialized evaluation. Addressing this gap requires implementation of standardized referral criteria, strengthened cross-sectoral networks, and regional accountability mechanisms. These findings provide a scalable framework for aligning decentralized care systems with evidence-based escalation pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.